Supplementary Table S3. ALFA-0701 - Adverse Events in Consolidation 2 from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia
| Autor: | Richard Pazdur, Ann T. Farrell, Marjorie Shapiro, Christopher M. Sheth, Jiang Liu, Lei Nie, Donna Przepiorka, Kelly J. Norsworthy, Charles Jewell, Antonina Aydanian, Pedro L. Del Valle, Jee Eun Lee, Chia-Wen Ko, Emily Y. Jen |
|---|---|
| Rok vydání: | 2023 |
| Popis: | Supplemental Table 3 describes the adverse events with corresponding risk differences between treatment arms during consolidation 2 of pivotal trial ALFA-0701. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|